STAT+: Johnson & Johnson advances IBD therapy, despite trial miss

A closely watched therapy developed by Johnson & Johnson failed to show a statistically meaningful improvement for IBD patients. global health research legal Newsletters Log In My Account Subscribe Now My Account Settings Complete your personal information for a more tailored experience Billing Log Out A decade of reporting from the frontiers of health and medicine Newsletters Log In My Account Subscribe Now Biotech Pharma Public Health Health Tech Policy Science First Opinion STAT+ STAT Events Search Log In Try STAT+ My Account Home Biotech Johnson & Johnson advances IBD therapy, despite trial miss The drugmaker plans to focus on…

Source: STAT News Pharma